Autor según el artículo: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; Auladell C; Camins A
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Folch Lopez, Jaume
Palabras clave: Synapses Novel therapies Nonsteroidal antiinflammatory drugs Neuroinflammation Dementia Clinical studies synaptic loss synapses receptor novel therapies neuropathologic assessment neuroinflammation mild cognitive impairment mast-cells hypothesis clinical studies brain amyloid-beta oligomers
Resumen: The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer's disease (AD) being the most common cause. In spite of decades of intensive research, no cure for AD has been found yet. However, some treatments that may change disease progression and help control symptoms have been proposed. Beyond the classical hypotheses of AD etiopathogenesis, i.e., amyloid beta peptide (Aβ) accumulation and tau hyperphosphorylation, a trend in attributing a key role to other molecular mechanisms is prompting the study of different therapeutic targets. Hence, drugs designed to modulate inflammation, insulin resistance, synapses, neurogenesis, cardiovascular factors and dysbiosis are shaping a new horizon in AD treatment. Within this frame, an increase in the number of candidate drugs for disease modification treatments is expected, as well as a focus on potential combinatory multidrug strategies.The present review summarizes the latest advances in drugs targeting Aβ and tau as major contributors to AD pathophysiology. In addition, it introduces the most important drugs in clinical studies targeting alternative mechanisms thought to be involved in AD's neurodegenerative process.
Áreas temáticas: Química Medicine (miscellaneous) Medicine (all) Medicina iii Medicina ii Medicina i Interdisciplinar Immunology and microbiology (miscellaneous) Immunology and microbiology (all) General immunology and microbiology General biochemistry,genetics and molecular biology Farmacia Enfermagem Educação física Economia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Cell biology Biotecnología Biodiversidade Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: jaume.folch@urv.cat
Identificador del autor: 0000-0002-5051-8858
Fecha de alta del registro: 2024-01-13
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.imrpress.com/journal/FBL/27/5/10.31083/j.fbl2705146
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Frontiers In Bioscience-Landmark. 27 (5): 146-
Referencia de l'ítem segons les normes APA: Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; Gudiño-Cabrera G; Ureña-Guerrero ME; Verdaguer E; Folch J; A (2022). Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease. Frontiers In Bioscience-Landmark, 27(5), 146-. DOI: 10.31083/j.fbl2705146
DOI del artículo: 10.31083/j.fbl2705146
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2022
Tipo de publicación: Journal Publications
Repositori URV